These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 22187891)

  • 21. [Psychopharmocotherapy of schizophrenia in forensic and general psychiatry].
    Stompe T; Schanda H
    Neuropsychiatr; 2011; 25(2):75-84. PubMed ID: 21672506
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Associations between adherence to guidelines for antipsychotic dose and health status, side effects, and patient care experiences.
    Dickey B; Normand SL; Eisen S; Hermann R; Cleary P; Cortés D; Ware N
    Med Care; 2006 Sep; 44(9):827-34. PubMed ID: 16932134
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Comparative evaluation of clinical practice guidelines for the treatment of schizophrenia].
    Delessert D; Pomini V; Grasset F; Baumann P
    Encephale; 2008 Jan; 34(1):93-100. PubMed ID: 18514156
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The quest for the pharmacological treatment of schizophrenia: from conventional neuroleptics to atypical antipsychotics and beyond].
    Dratcu L
    Vertex; 2010; 21(93):385-93. PubMed ID: 21218203
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Delays in adopting evidence-based dosages of conventional antipsychotics.
    Valenstein M; Copeland L; Owen R; Blow F; Visnic S
    Psychiatr Serv; 2001 Sep; 52(9):1242-4. PubMed ID: 11533400
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Can clinical practice guide a research agenda?
    Marder SR
    Schizophr Bull; 2002; 28(1):127-9. PubMed ID: 12047012
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Editor's introduction: antipsychotic prescribing practices.
    Essock SM
    Schizophr Bull; 2002; 28(1):1-4. PubMed ID: 12047008
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Drugs against schizophrenia: SBU fails to sort things out].
    Thelander S
    Lakartidningen; 2012 Aug 8-21; 109(32-33):1417; author reply 1418-9. PubMed ID: 22953431
    [No Abstract]   [Full Text] [Related]  

  • 29. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance.
    Hasan A; Falkai P; Wobrock T; Lieberman J; Glenthoj B; Gattaz WF; Thibaut F; Möller HJ;
    World J Biol Psychiatry; 2012 Jul; 13(5):318-78. PubMed ID: 22834451
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Focus on antipsychotic polypharmacy: evidence-based prescribing or prescribing-based evidence?
    Stahl SM
    Int J Neuropsychopharmacol; 2004 Jun; 7(2):113-6. PubMed ID: 14984629
    [No Abstract]   [Full Text] [Related]  

  • 31. Antipsychotic treatment in the maintenance phase of schizophrenia: An updated systematic review of the guidelines and algorithms.
    Shimomura Y; Kikuchi Y; Suzuki T; Uchida H; Mimura M; Takeuchi H
    Schizophr Res; 2020 Jan; 215():8-16. PubMed ID: 31784340
    [TBL] [Abstract][Full Text] [Related]  

  • 32. What is Missing in Treatment Guidelines?
    Carpenter WT
    Schizophr Bull; 2021 Mar; 47(2):269-270. PubMed ID: 33544848
    [No Abstract]   [Full Text] [Related]  

  • 33. PORT recommendations.
    Kane JM
    Schizophr Bull; 2004; 30(3):605-7. PubMed ID: 15631250
    [No Abstract]   [Full Text] [Related]  

  • 34. Medication patch may help people with schizophrenia.
    Nurs Stand; 2014 Aug; 28(50):10. PubMed ID: 25116524
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of individual fitness score for conformity of prescriptions to the "Guidelines For Pharmacological Therapy of Schizophrenia".
    Inada K; Fukumoto K; Hasegawa N; Yasuda Y; Yamada H; Hori H; Ichihashi K; Iida H; Ohi K; Muraoka H; Kodaka F; Ide K; Hashimoto N; Iga JI; Ogasawara K; Atake K; Takaesu Y; Nagasawa T; Komatsu H; Okada T; Furihata R; Kido M; Kikuchi S; Kubota C; Makinodan M; Ochi S; Takeshima M; Yamagata H; Matsumoto J; Miura K; Usami M; Kishimoto T; Onitsuka T; Katsumoto E; Hishimoto A; Numata S; Yasui-Furukori N; Watanabe K; Hashimoto R
    Neuropsychopharmacol Rep; 2022 Dec; 42(4):502-509. PubMed ID: 36254805
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inside the black box: the importance of monitoring treatment implementation.
    Essock SM; Covell NH; Weissman EM
    Schizophr Bull; 2004; 30(3):613-5. PubMed ID: 15631252
    [No Abstract]   [Full Text] [Related]  

  • 37. Antipsychotic dosing: found in translation.
    Remington G; Fervaha G; Foussias G; Agid O; Turrone P
    J Psychiatry Neurosci; 2014 Jul; 39(4):223-31. PubMed ID: 24467943
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Commentary on RANZCP clinical practice guidelines for the management of schizophrenia and related disorders - Section on pregnancy and schizophrenia.
    Judd F; Newman L
    Aust N Z J Psychiatry; 2017 Mar; 51(3):287-288. PubMed ID: 27687777
    [No Abstract]   [Full Text] [Related]  

  • 39. Looking back and looking forward: celebrating 20 years of the Cochrane Collaboration and celebrating release of exciting evidence based approaches to decreasing antipsychotic use in long-term care.
    Resnick B
    Geriatr Nurs; 2013; 34(6):443-4. PubMed ID: 24432387
    [No Abstract]   [Full Text] [Related]  

  • 40. Reducing inhibition: A promising new strategy for the treatment of schizophrenia.
    Page CE; Coutellier L
    EBioMedicine; 2018 Sep; 35():25-26. PubMed ID: 30131309
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.